Patients prescribed lercanidipine, a common high blood pressure medication, are being urgently advised to check their medication packets following a recall over incorrect dosage labeling. The Medicines and Healthcare Products Regulatory Agency (MHRA) announced that certain batches of the drug, manufactured by Recordati Pharmaceuticals, were mistakenly labeled as containing 10mg tablets when they actually hold 20mg doses.
More than 7,700 packs which have been distributed across the UK are affected by the recall. The MHRA warned that taking a 20mg dose instead of the prescribed 10mg could lead to side effects such as dizziness and excessive sleepiness. While the agency emphasized the risk is low for most patients, those with underlying health conditions or taking other medications may face heightened complications.
“Patients should check their lercanidipine packets immediately. If the box is marked 10mg but contains 20mg tablets, contact your GP, pharmacist, or NHS 111 for guidance. Do not stop taking your medication abruptly without consulting a healthcare professional, as this could pose further risks.” Dr. Alison Wright, MHRA’s Safety Director, stated.
The National Health Service has issued a warning, noting that individuals who unknowingly took the higher dose should monitor for symptoms and seek medical advice if concerned. Recordati Pharmaceuticals confirmed it is collaborating with the MHRA to investigate the cause of the labeling error and prevent future occurrences.
Pharmacies have also been instructed to quarantine affected batches and patients are urged to return mislabeled packets to the nearest pharmacy for replacement. Specific batch numbers have not been publicly disclosed, but individuals who are uncertain about their medication are advised to consult their healthcare provider promptly.
Recordati has apologized for the error and is working proactively with the MHRA to address the issue. The company is contacting customers who may have received the affected batch and is investigating the root cause of the problem.
High blood pressure can lead to serious health complications, including heart attacks and strokes. However, with proper treatment and lifestyle changes, patients can manage their condition and remain healthy. The MHRA and Recordati are prioritizing patient safety and working to minimize disruption to those affected.
This incident highlights critical oversight in pharmaceutical packaging, with the MHRA reinforcing the importance of robust quality checks to safeguard patient health.
Source: BBC
